Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.verified

ARQT

Price:

$8.94

Market Cap:

$1.03B

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known...[Read more]

Industry

Biotechnology

IPO Date

2020-01-31

Stock Exchange

NASDAQ

Ticker

ARQT

The PE Ratio as of April 2024 (TTM) for Arcutis Biotherapeutics, Inc. (ARQT) is -2.37

According to Arcutis Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.37. This represents a change of 32.97% compared to the average of -1.78 of the last 4 quarters.

Arcutis Biotherapeutics, Inc. (ARQT) Historical PE Ratio (quarterly & annually)

How has ARQT PE Ratio performed in the past?

The mean historical PE Ratio of Arcutis Biotherapeutics, Inc. over the last ten years is -19.28. The current -2.37 PE Ratio has changed 1.13% with respect to the historical average. Over the past ten years (40 quarters), ARQT's PE Ratio was at its highest in in the December 2023 quarter at -1.13. The PE Ratio was at its lowest in in the December 2018 quarter at -17.55.

Quarterly (TTM)
Annual

Average

-19.28

Median

-7.40

Minimum

-78.98

Maximum

-0.85

Arcutis Biotherapeutics, Inc. (ARQT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Arcutis Biotherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual PE Ratio = -0.85

Minimum Annual Increase = -74.15%

Minimum Annual PE Ratio = -78.98

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.85-66.31%
2022-2.54-49.06%
2021-4.98-32.70%
2020-7.40-62.60%
2019-19.77-3.17%
2018-20.42-74.15%

Arcutis Biotherapeutics, Inc. (ARQT) Average PE Ratio

How has ARQT PE Ratio performed in the past?

The current PE Ratio of Arcutis Biotherapeutics, Inc. (ARQT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.79

5-year avg

-7.11

10-year avg

-19.28

Arcutis Biotherapeutics, Inc. (ARQT) PE Ratio vs. Peers

How is ARQT’s PE Ratio compared to its peers?

Arcutis Biotherapeutics, Inc.’s PE Ratio is greater than Terns Pharmaceuticals, Inc. (-3.86), less than Amylyx Pharmaceuticals, Inc. (2.71), greater than Acumen Pharmaceuticals, Inc. (-3.59), greater than Inozyme Pharma, Inc. (-3.87), less than X4 Pharmaceuticals, Inc. (-2.03), greater than Icosavax, Inc. (-8.27), greater than Mirum Pharmaceuticals, Inc. (-7.02), greater than VectivBio Holding AG (-7.94), greater than Day One Biopharmaceuticals, Inc. (-7.38), greater than Mirati Therapeutics, Inc. (-5.32), greater than Apellis Pharmaceuticals, Inc. (-10.93), less than Spero Therapeutics, Inc. (3.13), less than Bolt Biotherapeutics, Inc. (-0.62), less than Coherus BioSciences, Inc. (-1.03), greater than Gracell Biotechnologies Inc. (-12.54), less than Neoleukin Therapeutics, Inc. (-0.98), greater than Theseus Pharmaceuticals, Inc. (-3.19), less than Monte Rosa Therapeutics, Inc. (-2.35), greater than Design Therapeutics, Inc. (-3.21), less than Erasca, Inc. (-2.30),

Build a custom stock screener for Arcutis Biotherapeutics, Inc. (ARQT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcutis Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arcutis Biotherapeutics, Inc. (ARQT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arcutis Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Arcutis Biotherapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Arcutis Biotherapeutics, Inc. (ARQT)?

What is the highest PE Ratio for Arcutis Biotherapeutics, Inc. (ARQT)?

What is the 3-year average PE Ratio for Arcutis Biotherapeutics, Inc. (ARQT)?

What is the 5-year average PE Ratio for Arcutis Biotherapeutics, Inc. (ARQT)?

How does the current PE Ratio for Arcutis Biotherapeutics, Inc. (ARQT) compare to its historical average?